WASHINGTON, June 21, 2018 /PRNewswire-USNewswire/ — The American Society of Hematology (ASH) will collaborate with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), World Federation of Hemophilia (WFH), and the University of Kansas Medical Center to develop clinical practice guidelines on the diagnosis and management of …
Tag Archives: Von Willebrand disease
June, 2018
March, 2017
-
22 March
Shire’s Hereditary Thrombotic Thrombocytopenic Purpura Treatment Receives Fast Track Status from the FDA
Lexington, Mass. – March 22, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for recombinant ADAMTS13 (SHP655 – historically known as BAX930) for treatment of acute episodes of hereditary thrombotic thrombocytopenic purpura (hTTP) in …
December, 2016
-
5 December
Shire’s Vonvendi Succeeds in Late-Stage Study in Patients with Von Willebrand Disease
Lexington, Mass. – December 2, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases and other highly specialized conditions, today announced topline results from a Phase 3 clinical trial of VONVENDITM [von Willebrand factor (Recombinant)] to treat bleeds in elective …
December, 2015
-
8 December
Baxalta Wins FDA Approval for Vonvendi for Treatment of Patients with Von Willebrand Disease
BANNOCKBURN, Ill.–(BUSINESS WIRE)– Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved VONVENDI [von Willebrand factor (Recombinant)]. VONVENDI is the first and only recombinant treatment for …
April, 2015
-
14 April
CSL Behring Marks World Hemophilia Day by with Significant Contributions to the World Federation of Hemophilia
In recognition of World Hemophilia Day, held on April 17, CSL Behring announced that it is donating ten million international units (IUs) of bleeding disorder protein therapies and contributing a significant financial contribution to the World Federation of Hemophilia (WFH). CSL Behring said that it has once again committed to …